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Abstract
The pathogenesis and progression of atherosclerosis are integrally
connected to the concentration and function of lipoproteins in
various classes. This review examines existing and emerging
approaches to modify low-density lipoprotein and lipoprotein (a),
triglyceride-rich lipoproteins, and high-density lipoproteins,
emphasizing approaches that have progressed to clinical evalua-
tion. Targeting of nuclear receptors and phospholipases is also
discussed.
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Introduction
Ischemic heart disease and cerebrovascular disease due to athero-
sclerosis remain leading causes of death in the world. Lipoprotein
abnormalities play a key role in the pathogenesis of these diseases.
Low-density lipoprotein (LDL), triglyceride-rich lipoproteins, and
high-density lipoprotein (HDL) may contribute to the development
and progression of atherosclerosis and its complications. Numerous
strategies to modify each of the principal classes of lipoproteins
have been or are currently under investigation. This review primarily
focuses on those approaches that have progressed to clinical
evaluation or implementation.
LDL, triglyceride-rich lipoproteins, and HDL comprise the
three principal lipoprotein classes. The primary function of LDL
is to deliver essential cholesterol to peripheral tissues. Triglycer-
ide-rich lipoproteins carry a cargo of energy substrate (fatty
acids) from intestine to liver and to peripheral tissues for fat
storage and oxidative metabolism. HDL participates in reverse
cholesterol transport to remove excess cholesterol stores from
peripheral sites for biliary excretion. Each lipoprotein class may
affect the development and progression of atherosclerosis and
its complications. Numerous strategies to modify each of the
principal classes of lipoproteins have been or are currently under
investigation (Table 1, Fig 1).
Targets for reduction of LDL and related
atherogenic lipoproteins
Statin drugs have been the cornerstone of lipid-modifying therapy
for more than a quarter century. Statins inhibit 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG CoA) reductase, which is the rate-limiting
step for cholesterol synthesis. A reduction in hepatic cholesterol
synthesis and hepatocyte cholesterol concentration results in upreg-
ulation of LDL receptor expression on hepatocytes and enhanced
clearance of LDL and other atherogenic lipoproteins from the circu-
lation. Through this mechanism, statins can reduce concentrations
of LDL-C by as much as 50–60%, with accompanying reductions of
triglyceride-rich lipoproteins and modest increases in HDL-C. A
large body of data from controlled clinical trials indicates that each
1 mmol/l reduction in LDL-C produced by statin treatment is associ-
ated with approximately 12% reduction in all-cause mortality and
20% reduction in cardiovascular morbidity (Baigent et al, 2005). At
usual doses, statins reduce cardiovascular risk by 25–30%. Part of
the clinical efficacy of statins may also be attributable to non-lipid,
or ‘pleiotropic’ effects related to effects of HMG CoA reductase
inhibition on isoprenoid intermediates in cholesterol biosynthesis
(Davignon, 2004; Nohria et al, 2009; Zhou & Liao, 2010). However,
substantial residual cardiovascular risk remains despite effective
statin treatment. The extent to which this residual risk is attribut-
able to lipoprotein abnormalities, and might be reduced by addi-
tional lipoprotein-modifying therapies, remains unknown. To date,
no second lipid-modifying therapy, added to primary treatment with
statins, has been proven to reduce cardiovascular risk. However,
promising new targets and new approaches to established targets
are being investigated.
Cholesterol absorption
Interference with cholesterol absorption can lower circulating
concentrations of LDL-C. Bile acid sequestrants such as cholestyr-
amine lower LDL-C levels up to 25%. As monotherapy, cholestyr-
amine was shown to reduce the risk of myocardial infarction (Lipid
Research Clinics Program, 1984). However, use of bile acid seques-
trants is limited by gastrointestinal side effects, interference with
absorption of other drugs, and exacerbation of hypertriglyceridemia.
A newer bile acid sequestrant, colesevelam, has a relatively low
incidence of gastrointestinal side effects (Davidson et al, 1999).
A target for the inhibition of intestinal cholesterol absorption is
Niemann-Pick C1-like 1 (NPC1L1). Ezetimibe inhibits cholesterol
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absorption by blocking the function of NPC1L1 (Garcia-Calvo et al,
2005) and lowers LDL-C in patients by approximately 15%. In a
study of patients with heterozygous familial hypercholesterolemia
followed for 24 months, there was no difference in intima-media
thickness with ezetimibe and simvastatin, compared with placebo
and simvastatin (Kastelein et al, 2008). However, there are no data
to date indicating whether or not the additional reduction of LDL-C
resulting from addition of ezetimibe to statin translates into addi-
tional reduction of cardiovascular risk. This hypothesis is being
tested in the IMPROVE-IT trial, with results expected in 2014 (Califf
et al, 2010).
Squalene synthase
Squalene synthase acts downstream from HMG CoA reductase to
convert farnesyl pyrophosphate to squalene, the first committed
step in cholesterol biosynthesis. Inhibition of squalene synthase
lowers plasma cholesterol levels without affecting the synthesis of
upstream intermediates implicated in the development of myopathy
with statins (Nishimoto et al, 2007). Lapaquistat acetate is a squa-
lene synthase inhibitor that reduced LDL-C by 20% and lowered
C-reactive protein levels by 25%. It progressed to evaluation in
Phases 2 and 3 clinical trials. However, development of lapaquistat
was halted due to two cases of severe liver enzyme elevation,
coupled with evidence that the strategy might not reduce muscle
toxicity (Stein et al, 2011). No other squalene synthase inhibitors
have reached advanced stages of clinical development.
Expression of apolipoprotein B100
Apolipoprotein (apo) B-containing lipoproteins include LDL, very
low-density lipoprotein (VLDL), and VLDL remnants. Because these
lipoproteins may promote atherosclerosis, strategies to prevent
expression of apoB are attractive. However, interference with
hepatic export of apoB-containing lipoproteins also has the potential
to promote hepatic steatosis.
Mipomersen is a 20-base, 20-O-(2-methoxy) ethyl-modified anti-
sense oligonucleotide that targets mRNA encoding apoB100. It
reduces circulating levels of all lipoprotein species containing
apoB100 in humans. In Phases 2 and 3 clinical trials of mipomersen
as monotherapy or added to statins in patients with familial hyper-
cholesterolemia (FH), LDL-C reductions of up to 47% were observed
(Visser et al, 2012). Because mipomersen does not significantly
affect intestinal apoB48 expression, intestinal fat absorption is unaf-
fected and intestinal steatosis is avoided (Crooke et al, 2005).
However, treatment with mipomersen was associated with injection
site reactions, flu-like symptoms, and hepatic steatosis with elevated
liver transaminases (Visser et al, 2012).
Mipomersen is currently approved for the treatment of homozygous
familial hypercholesterolemia. However, the long-term benefit/risk
profile remains to be determined and might be influenced by
tolerability or hepatic safety. Other approaches to knockdown
apoB100, including small interfering RNAs, are under investigation
(Tadin-Strapps et al, 2011).
VLDL assembly – ACAT and MTP
Another approach to reduce LDL is to prevent hepatic secretion of
its precursor lipoprotein, VLDL, by interfering with the lipidation of
apoB. Two enzymes involved in this process, acyl-CoA/cholesterol
acyltransferase (ACAT) and microsomal triglyceride transfer protein
(MTP), have been targeted.
ACAT1 and ACAT2 are expressed in macrophages as well as liver
and intestine where they are involved in accumulation of cholesterol
ester, foam cells, atherosclerosis, and providing cholesterol ester to
secreted VLDL and chylomicrons (Lee et al, 2000; Leon et al, 2005).
Surprisingly, clinical trials that used intravascular ultrasound to
evaluate non-specific ACAT inhibitors demonstrated that treatment
had a neutral to adverse effect on coronary atherosclerosis (Tardif
et al, 2004; Nissen et al, 2006). The explanation may be related to
toxic effects of increased free cholesterol in macrophages. Selective
ACAT2 inhibition might remain a plausible approach to retard
atherosclerosis (Ohshiro & Tomoda, 2011).
MTP transfers neutral lipids to nascent apoB and thereby affects
the rate of VLDL and chylomicron synthesis. Loss-of-function muta-
tion of MTP is the cause of abetalipoproteinemia, a condition with
defective fat absorption and the absence of circulating apoB-containing
lipoproteins. Lomitapide is a small molecule inhibitor of MTP
that was shown to lower LDL-C levels by 50% in patients with
homozygous FH and has been approved for the use in that condition
(Cuchel & Rader, 2013). Although lomitapide is effective in lowering
Glossary
Apheresis a procedure used to remove a substance from
blood circulation. Whole blood is drawn from the
body by large catheter and separated into
different blood components. The desired
substance can then be removed, with reinfusion
of remaining blood products to the body.
Atherosclerosis the process of cholesterol plaque deposition and
inflammation along arterial walls. It can result in
obstruction to blood flow and a tendency to
thrombosis with sudden vessel occlusion.
Chylomicrons large lipoprotein particle that carries dietary lipid
and is rich in triglyceride.
Foam cells macrophages or immune cells containing excess
cholesterol, largely due to uptake of oxidized LDL.
High-density
lipoprotein (HDL)
ApoA1-containing lipoprotein; major function is





formed by action of lipases on very low-density
lipoproteins, resulting in increased cholesterol
and decreased triglyceride content and smaller
size, compared with VLDL.
Lipoprotein particles consisting of surface proteins and
phospholipid and a neutral lipid core, functioning
to transport of lipids throughout the circulation.
Low-density
lipoprotein (LDL)
ApoB-containing lipoprotein. Major carrier of
cholesterol esters to peripheral cells.
Myopathy muscle disease that in general describes muscle
weakness or pain.
Hepatic steatosis caused by an imbalance of lipid uptake or
synthesis compared with clearance from the liver.
Very low-density
lipoprotein
carries triglycerides and cholesterol from liver to
peripheral tissue and contains apolipoproteins B,
C, and E.
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LDL-C, its use is unlikely to extend beyond FH because of a high
incidence of gastrointestinal symptoms related to malabsorption of
fat and hepatic steatosis related to inhibition of hepatic lipid export
(Cuchel et al, 2013).
Thyromimetics or tiromes
Thyroid hormone exerts tissue-specific effects, with the thyroid
hormone receptor b1 isoform (TR b1) predominating in liver and
involved in cholesterol metabolism (Gullberg et al, 2000). TR b1
activation depletes intracellular cholesterol concentration, leading to
increased expression of the LDL receptor in hepatocytes. Hypolipi-
demic effects of TR b1 activation are also increased biliary choles-
terol excretion through stimulation of cholesterol 7a-hydroxylase
(CYP7A1) expression (Lin et al, 2012), downregulation of sterol
regulatory element-binding protein (SREBP)-1c (Hashimoto et al,
2006), and non-classical signaling pathways (Cordeiro et al, 2013).
The TR b1 agonists such as eprotirome have been evaluated in
clinical trials. On a background of statin treatment, eprotirome
lowered LDL-C up to 32%, associated with reductions of apoB,
triglycerides, and Lp(a) (Ladenson et al, 2010). Eprotirome was
effective in decreasing levels of atherogenic lipoproteins in patients
with hypercholesterolemia (Angelin et al, 2014). However, a recent
Phase 3 trial was terminated after liver injury was noted in humans
and cartilage injury noted in preclinical data with dogs (Sjouke et al,
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Arrows indicate direction and magnitude of lipoprotein change.
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↑↑ or ↓↓ indicates 30–60% change (increase/decrease).
↑↑↑ or ↓↓↓ indicates > 60% change (increase/decrease).
→ indicates neutral effect/no change.
EMBO Molecular Medicine Vol 6 | No 10 | 2014 ª 2014 The Authors
EMBO Molecular Medicine Evolving targets for lipid-modifying therapy Rose Q Do et al
1218
Published online: August 29, 2014 
PCSK9
broprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted
protein that regulates the hepatic LDL receptor (LDLR), and in turn
circulating levels of LDL-C (Akram et al, 2010; Do et al, 2013).
When an LDL particle binds to a hepatocyte LDLR in the absence of
PCSK9, the LDL/LDLR complex undergoes endocytosis. In the acidic
endosome, the LDLR dissociates from LDL and is recycled back to












































































































































Figure 1. Schematic indicating potential targets for lipid metabolism.
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undergoes lysosomal degradation. When LDL binds to LDLR in the
presence of PCSK9, the LDLR does not dissociate from LDL and is
instead channeled toward lysosomal degradation. This action
reduces LDLR density on the surface of hepatocytes, allowing levels
of LDL-C to rise.
Gain-of-function mutations in PCSK9 are a cause of familial
hypercholesterolemia and premature coronary heart disease, while
loss-of-function mutations are associated with lifelong low levels of
LDL-C and substantially reduced coronary heart disease risk (Davignon
et al, 2010). Statins increase the expression of PCSK9, an effect that
may attenuate the LDL-C lowering produced with these agents
(Dubuc et al, 2004). Conversely, therapeutic interference with
PCSK9 expression or action with small interfering RNA or monoclo-
nal antibody (Frank-Kamenetsky et al, 2008; Dias et al, 2012; Stein
et al, 2012) allows greater recycling of LDLR to the hepatocyte
surface, resulting in lower LDL-C levels. Phase 2 clinical trials have
demonstrated efficacy of PCSK9 antibody in achieving LDL-C reduc-
tions of up to 73% when added on to statin background therapy. In
this trial when atorvastatin dose was increased from 10 to 80 mg
daily and PCSK9 antibody was added, LDL-C was reduced by 73%,
as compared to a 17% reduction with atorvastatin 80 mg alone
(Roth et al, 2012) (Fig 2). Large Phase 3 clinical trials are testing the
efficacy of PCSK9 antibodies to reduce major adverse cardiovascular
events (NCT01764633 and NCT01663402). Because inhibition of
PCSK9 does not impair hepatic lipid export, this approach is
unlikely to cause hepatic steatosis. However, it is premature to
assess whether very low LDL-C levels achieved in some patients
treated with PCSK9 antibodies will lead to adverse long-term effects,
or whether immunologic reactions to the antibodies will occur.
Lipoprotein (a)
Lipoprotein (Lp)(a) is an LDL-like particle in which apoB is cova-
lently bound to apo(a). Both moieties may mediate atherogenicity.
Apo(a) is structurally similar to plasminogen and can interfere
with plasminogen activation and fibrinolysis (Hancock et al,
2003). Lp(a) can also carry oxidized phospholipids that may be
pro-inflammatory (Wiesner et al, 2013). Epidemiologic data
suggest that a high level of Lp(a) is an independent risk factor for
the development of cardiovascular disease (Erqou et al, 2009).
Serum levels of Lp(a) are influenced by genetic factors (Boerwin-
kle et al, 1992), but not by diet or lifestyle factors (Thomas et al,
1997). In cohort studies, cardiovascular risk associated with Lp(a)
is independent of smoking, diabetes, hypertension, as well as LDL-
C (Luc et al, 2002) (Fig 3).
Niacin exerts the greatest Lp(a) lowering effects among
currently available lipid-modifying therapies. However, a 21%
average reduction in Lp(a) with niacin was not associated with a
lower event rate in the niacin arm, compared with placebo. This
may indicate either that Lp(a) is not causally related to risk or
that niacin produced other undesirable effects that negated a
Figure 2. Effect of PCSK9 inhibition on low-density lipoprotein (LDL) cholesterol levels.
Patients with primary hypercholesterolemia were treated with atorvastatin 10 mg during a run-in period and then randomly assigned to treatment with atorvastatin
80 mg daily with alirocumab (SAR236553) every 2 weeks, atorvastatin 10 mg daily with alirocumab (SAR236553) every 2 weeks, or atorvastatin 80 mg daily with placebo
every 2 weeks. Alirocumab produced a profound reduction in LDL-C compared with placebo. There was minimal additional LDL-C reduction when alirocumab was
administered with atorvastatin 80 mg, compared with atorvastatin 10 mg daily [Reproduced with permission from Roth et al (2012)].
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benefit of raising Lp(a) (Boden et al, 2011). PCSK9 antibodies
lower Lp(a) concentrations by mechanisms as yet unknown
(McKenney et al, 2012). Lipoprotein apheresis can also remove
Lp(a) from the circulation. In a prospective observational study
in patients with elevated Lp(a), the initiation of lipoprotein
apheresis was accompanied by a reduced incidence of cardiovas-
cular events (Leebmann et al, 2013). Novel approaches to the
reduction of Lp(a) involve the use of antisense oligonucleotides.
Mipomersen reduces Lp(a) by approximately 25% (Visser et al,
2012) and antisense oligonucleotide to apo (a) has been shown
to lower Lp(a) concentrations in a Phase 1 clinical study (Viney
et al, 2013). The latter approach may provide the best tool to
determine whether Lp(a) plays a direct, causative role in cardio-
vascular disease.
Targets for reduction of triglyceride-rich lipoproteins
Triglyceride-rich lipoproteins include VLDL, chylomicrons and the
remnant particles formed from them upon the action of lipases.
These particles contain apoB, C, and E and are believed to be
atherogenic. Post hoc and meta-analyses of statin trials suggest that
higher level of triglyceride-rich lipoproteins and their associated
cholesterol correlate with higher cardiovascular risk (Miller et al,
2008; Bruckert et al, 2011).
Niacin and fibrates reduce triglycerides and have been in thera-
peutic use for many years. Early studies of these agents indicated a
cardiovascular benefit. Although subsequent studies utilizing these
agents in addition to statins failed to show overall benefit (Boden
et al, 2011), post-hoc analyses suggest that patients with significant
baseline hypertriglyceridemia benefit from fibrates (Lee et al, 2011).
Other strategies to reduce triglyceride-rich lipoproteins, outlined
below, are under active investigation.
Omega-3 fatty acids
Population studies demonstrate that cohorts with low levels of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
have higher levels of cardiovascular risk. Omega-3 fatty acids are
found in fish oils and plants and have been observed to lower
triglyceride levels, improve endothelial function, and have favor-
able effects on thrombotic and arrhythmic potential. The triglycer-
ide-lowering effects of omega-3 fatty acids are due to multiple
mechanisms, including stimulation of transcription factors such as
PPAR a, increased hepatic and extrahepatic fatty acid oxidation,
and decreased hepatic incorporation of fatty acids into triglyceride
resulting in decreased VLDL synthesis (Shearer et al, 2012).
Despite efficacy in triglyceride lowering, data indicating a cardio-
vascular benefit alone or when added to statins are inconclusive
(Rizos et al, 2012). A concentrated formulation of EPA, eicosa-
pent ethyl, is being evaluated for effects on lipoproteins, biomar-
kers of cardiovascular risk, and clinical cardiovascular outcomes
(Ballantyne et al, 2012; NCT01492361).
Apolipoprotein C-III
ApoC-III is located on the surface of triglyceride-rich lipoproteins
including VLDL, chylomicrons, and their remnants and is impli-
cated in cardiovascular disease. High levels of apoC-III are associ-
ated with delayed clearance of VLDL (Aalto-Setala et al, 1992)
and may exert pro-inflammatory effects at the level of the artery
wall (Kawakami et al, 2006). Further supporting its atherogenic
role, those with dysfunctional apoC-III have lower cardiovascular
risk. In two recent genetic studies, subjects with loss-of-function
mutations in the gene encoding apoC-III were noted to have 39–
44% lower levels of triglycerides and ~40% lower risk of coro-
nary heart disease (Jørgensen et al, 2014; TG and HDL Working
Group, 2014). An apoC-III antisense oligonucleotide has demon-
strated substantial reductions in apoC-III, triglycerides (Fig 4) in
Figure 3. Relation of Lp(a) and LDL-C to CHD risk.
Prospective cohort study of 9,133 middle-aged men, without history of CHD and not on lipid-lowering therapy. In models adjusted for smoking, diabetes, and
hypertension, levels of Lp(a) and LDL-C were independently predictive of incident CHD [Drawn from data in Luc et al (2002)].
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addition to elevations of HDL-C, without inducing hepatic steato-
sis (Graham et al, 2013). This agent is currently being evaluated
in patients with severe hypertriglyceridemia. The impact of this
approach on cardiovascular risk has not yet been studied.
ApoC-III is also present on HDL particles. It is uncertain whether
ApoC-III on HDL conveys pro- or anti-atherogenic properties
(Cho, 2009; Riwanto et al, 2013).
Diacylglycerol acyltransferase (DGAT)
DGAT is an enzyme expressed in small intestine, liver, and adipose
tissue. DGAT isozyme 1 is involved in a final committed step of
triglyceride synthesis from diacylglycerol. Inhibition of the enzyme
may work to reduce serum triglyceride concentrations. Small mole-
cule inhibitors have been developed, but clinical application is likely
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Figure 4. Effects of apolipoprotein C-III antisense oligonucleotide (ASO).
(A) Effects of VLDL-associated apoC-III in mice. Mice were administered control ASO or one of two doses of apoC-III ASO for 6 weeks. Western blot demonstrates a
dose-dependent reduction of VLDL-associated apoC-III protein. (B) Effects of apoC-III ASO on circulating apoC-III and triglycerides in healthy human volunteers. ASO was
administered by subcutaneous injections with loading dose followed by three weekly doses of either 50, 100, 200, or 400 mg. A dose-dependent response was
demonstrated, with up to 75% reduction in apoC-III and 50% reduction in triglycerides, sustained over 50 days [Reproduced with permission from Graham et al (2013)].
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Apolipoprotein E
ApoE is a ligand for receptor-mediated clearance of chylomicron
and VLDL remnants, which are particles that may promote athero-
sclerosis directly or through the action of lipases to release toxic
products of lipolysis (Goldberg et al, 2011). ApoE also participates
in the biogenesis of HDL, as it is recycled from triglyceride-rich
lipoproteins in the liver (Zannis et al, 2008). ApoE mimetic
peptides have been developed that exert anti-inflammatory effects,
promote HDL function in vitro (Zhao et al, 2011), and oppose
atherosclerosis in vivo. In LDL receptor knockout mice prone to
atherosclerosis, ApoE mimetic peptides reduce plasma cholesterol
and the extent of vascular lesions (Handattu et al, 2013). One
ApoE mimetic peptide, AEM-28, has been granted orphan drug
status by the US Food and Drug Administration and may enter
early phase clinical testing.
HDL and related atheroprotective lipoproteins
HDL particles and associated apolipoprotein A-I are believed to be
anti-inflammatory and atheroprotective (Besler et al, 2012). Experi-
mental data support the concept that HDL and/or apoA-1 have
vascular anti-inflammatory effects. For example, administration of
reconstituted HDL to animals has been shown to reduce expression
of adhesion molecules in vascular endothelium and to attenuate
the inflammatory response to experimental arterial injury (Nicholls
et al, 2005). Additionally, HDL may promote the expression of
endothelial nitric oxide synthase and exert anti-thrombotic effects
(Barter et al, 2004). Several large population studies reported an
inverse relationship between HDL-C levels and prospective risk of
cardiovascular events (Castelli et al, 1986), independent of athero-



























































































Figure 5. Effect of dalcetrapib on HDL-C and cardiovascular risk after ACS.
Dalcetrapib was administered to patients with recent ACS on background statin therapy. While dalcetrapib raised HDL-C by 30% compared with placebo (top), there
was no difference between groups in the primary endpoint of death from coronary heart disease, non-fatal myocardial infarction, hospitalization for unstable angina,
resuscitation after cardiac arrest, or stroke from presumed atherothrombotic cause (bottom) [Reproduced with permission from Schwartz et al (2012)].
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HDL facilitates reverse cholesterol transport and cholesterol
efflux from peripheral tissues. Subpopulations of HDL interact with
different membrane bound transporters such as ATP binding
cassette A1 (ABCA1), ATP binding cassette G1 (ABCG1), and scav-
enger receptor-BI (SR-BI) to assist in cholesterol efflux (Acton et al,
1996; Vaughan & Oram, 2006). Cholesterol is transferred to HDL
particles, esterified by lecithin/cholesterol acyltransferase (LCAT),
and then transported to the liver for excretion.
Yet, agents that substantially raised HDL-C failed to demonstrate
corresponding clinical benefit (Boden et al, 2011; Schwartz et al,
2012). In epidemiologic analyses, cardiovascular risk is mainly
evident at the lowest levels of HDL-C and does not necessarily
support risk reductions by raising HDL-C to very high levels. More-
over, the protein cargo of HDL may be altered in patients with
vascular disease and less protective (Besler et al, 2012; Riwanto
et al, 2013). Despite these caveats, numerous approaches to modify
HDL concentration and/or function continue to be evaluated.
Niacin
Of currently available drugs, niacin is the most effective at raising
HDL-C, increasing levels by as much as 33% (Illingworth et al,
1994). The lipid-modifying effects of niacin are thought to be medi-
ated by activation of G protein-coupled receptors in adipose tissue
and liver leading to reduced lipolysis and hepatic VLDL synthesis,
respectively (Kamanna & Kashyap, 2008). While early data demon-
strated cardiovascular benefit (Canner et al, 1986), more recent clin-
ical trials have failed to demonstrate a clinical benefit of niacin in
statin-treated patients (Boden et al, 2011). These data suggest that
alternative HDL-targeted therapies are required if this approach is to
achieve reductions in cardiovascular risk.
Cholesteryl ester transfer protein inhibitors
Cholesteryl ester transfer protein (CETP) promotes the movement of
esterified cholesterol from HDL to VLDL and LDL particles, in
exchange for triglyceride. Lower CETP activity has been associated
with higher HDL-C levels and lower cardiovascular event rates in
some, but not all analyses (Thompson et al, 2008; Ritsch et al,
2010). Clinical development of torcetrapib was halted prematurely
due to increased cardiovascular morbidity and mortality (Barter
et al, 2007). This was potentially attributed to off-target effects
including upregulation of cortisol and aldosterone synthesis and
elevated blood pressure (Forrest et al, 2008).
Dalcetrapib is a CETP inhibitor without effects on neurohor-
mones and with minimal if any effect on blood pressure. However,
despite increasing HDL-C by approximately 30%, dalcetrapib had
no effect on vascular endothelial function (Luscher et al, 2012),
carotid atherosclerosis (Fayad et al, 2011), or cardiovascular events
(Schwartz et al, 2012) (Fig 3). Notably, dalcetrapib has minimal
effects on LDL-C. Anacetrapib and evacetrapib are CETP inhibitors
with pronounced LDL-lowering as well as HDL-raising effects
(Nicholls et al, 2011a,b; Gotto et al, 2014) that are undergoing
evaluation in Phase 3 cardiovascular outcome trials.
Regulators of apolipoprotein A-I synthesis
Hepatic production of apoA-I results in generation of nascent, lipid-
deplete HDL particles, which enter the systemic circulation and
carry out their biological activities. The bromodomain and extra-
terminal (BET) domain inhibitor, RVX-208, induces hepatic apoA-I
synthesis. RVX-208 administration increased cholesterol efflux
capacity in non-human primates (Bailey et al, 2010). In statin-
treated patients with coronary disease, RVX-208 produced modest
dose related increases in apoA-I and HDL-C. This was driven
predominantly by increases in large HDL particles, suggesting that
cholesterol mobilization to functional HDL particles was occurring
(Nicholls et al, 2011a,b). In a subsequent study in patients with low
HDL-C levels, modest coronary plaque regression was demonstrated
on serial intravascular ultrasound, but changes with RVX-208 did
not differ significantly from placebo (Nicholls et al, 2013). Increases
in hepatic transaminase levels were more frequent with RVX-208
than placebo. The effect of RVX-208 on cardiovascular outcomes
remains unknown.
HDL infusion therapy
Infusing HDL or apoA-1 presents a conceptually simple, but chal-
lenging approach. Infusion of lipid-deplete forms of HDL has favor-
able effects on atherosclerotic plaque, endothelial function, and
surrogate markers of reverse cholesterol transport (Spieker et al,
2002; Tardy et al, 2014). Intravenous infusions of complexes
containing the apoA-I variant, apoA-I Milano and phospholipid
(ETC-216) resulted in regression of coronary atherosclerosis
measured by serial intravascular ultrasound in patients with a
recent acute coronary syndrome (Nissen et al, 2003). Another
approach has been infusion of complexes of wild-type apoA-I and
phospholipid (CSL-111). This agent produced a trend toward regres-
sion of coronary atherosclerotic plaque on serial intravascular ultra-
sound imaging, but liver transaminase elevations required cessation
of testing of the highest dose (Tardif et al, 2007). Challenges in
producing large quantities of infusible HDL-mimetic complexes
appear to have been overcome, and development of several agents
is proceeding.
Delipidated HDL
A unique approach to HDL therapeutics involves the selective delipi-
dation of a patient’s HDL, which is subsequently reinfused. Poten-
tially, the lipid-poor HDL has greater capacity for cholesterol efflux.
A small imaging study demonstrated coronary plaque regression
with this approach (Waksman et al, 2010).
Mimetic peptides
Synthetic production of apoA-I presents a considerable challenge.
In contrast, an alternative approach is in preparing short peptide
sequences that lack genetic homology to apoA-I, but similarly
form an amphipathic helix and associate effectively with lipids.
Preclinical studies using these peptides have demonstrated favor-
able effects on cholesterol efflux, LCAT activation, inflammatory
and oxidative pathways, and ultimately atherosclerotic plaque
(Datta et al, 2001; Bielicki et al, 2010). CER-001, an HDL-mimetic
made up of apoA-I and phospholipids, has been associated with
reduction of vascular inflammation and atherosclerotic regression
after short-term administration in mice (Tardy et al, 2014) as well
as cholesterol mobilization in humans. In a Phase 2 trial, the
primary endpoint of reducing atheroma volume compared with
placebo was not reached (Tardif et al, 2014). However, the safety
profile has thus far been acceptable, and the drug may be effective
in reverse lipid transport. Thus, further study in clinical trials may
be warranted.
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Reverse cholesterol transport targets
Increasing expression of ABCA-1 provides a potential opportunity to
target a major factor implicated in cholesterol efflux, as opposed to
simply increasing carrier (apoA-1 or HDL) capacity. However, work
in this field has not advanced clinically.
Similarly, development of chemical inhibitors of microRNA
elements implicated in the regulation of lipid metabolism may be
beneficial. MicroRNA (miR)-33 is an intronic microRNA that
suppresses ABCA-1 expression and reduces HDL-C levels (Rayner
et al, 2010). Early preclinical experience with miR-33 inhibitors
demonstrates variable effects on atherosclerosis in animal models
(Marquart et al, 2013; Rotllan et al, 2013). Given the central role of
LCAT in reverse cholesterol transport by HDL, LCAT agonists have
been developed and are undergoing preclinical evaluation (Chen
et al, 2012).
HDL functional modification
Given disappointing results of HDL-C raising therapies in recent
clinical trials (Barter et al, 2007; Boden et al, 2011), there is
increasing interest in qualitative features of HDL function. HDL
particles circulate as a heterogeneous population of lipoproteins,
differing in size, shape, protein, and lipid composition (Rosenson
et al, 2011). Furthermore, mass spectrometry has demonstrated
more than 100 individual proteins that can be carried on HDL
particles, many with activities beyond lipid metabolism, and many
that are altered in patients with vascular disease compared with
healthy control (Riwanto et al, 2013). Data indicating that choles-
terol efflux capacity is a better predictor of atherosclerotic burden
than HDL-C concentration suggest that HDL quality may be a
better indicator of the efficacy of novel HDL-targeted therapies
(Hafiane et al, 2014).
Other approaches affecting lipoprotein metabolism
Nuclear receptors
Nuclear receptors including liver X receptors (LXRs), peroxisome
proliferator-activated receptors (PPARs), and farnesoid X receptors
(FXR) play a central role in lipid metabolism. The reader is referred
to other reviews for discussion of bile acid receptors, including FXRs
(Porez et al, 2012).
Liver X receptor
LXRs are thought to serve as cholesterol sensors that when acti-
vated, increase biliary cholesterol excretion, reduce intestinal
cholesterol absorption, and promote reverse cholesterol transport.
LXR agonists have been demonstrated to attenuate atherosclerosis
in animal models (van der Hoorn et al, 2011). However, a poten-
tially limiting factor in clinical treatment with LXR agonists is the
stimulation of hepatic lipogenesis (Fievet & Staels, 2009). LXR agon-
ists have been demonstrated to attenuate atherosclerosis in animal
models (Kappus et al, 2014). Some LXR agonists have been evalu-
ated in early stage clinical trials (Katz et al, 2009; NCT00796575,
NCT00836602, NCT01651273, NCT01651273), but their develop-
ment for cardiovascular disease appears to have been halted. It
remains uncertain whether agents can be developed to exploit the
potential benefits of LXR activation while avoiding hypertriglyceri-
demia and hepatic steatosis.
Peroxisome proliferator-activated receptors (PPARs)
PPARs (a, c, or d) play important roles in the regulation of fatty acid
and lipoprotein metabolism. Among their principal actions, PPARa
promotes fatty acid oxidation in liver and muscle, lowers circulating
triglycerides and apoC-III, and raises HDL-C, PPARc promotes fatty
acid uptake by adipocytes and lowers circulating fatty acids, and
PPARd promotes fatty acid oxidation in muscle and adipose tissue.
Fibrate and thiazolidinedione drugs are ligands of PPARa and
PPARc, respectively. Early studies showed that gemfibrozil, a
fibrate, reduced cardiovascular morbidity and mortality (Frick et al,
1987; Robins et al, 2001). However, subsequent studies evaluating
the addition of fibrates to statins have not demonstrated clinical
benefit (ACCORD Study Group, 2010). Yet, meta-analysis indicates
that fibrates may confer clinical benefit in patients with triglycer-
ide levels at least 200 mg/dl, even with statin co-treatment
(Bruckert et al, 2011). In this regard, it may be premature to
conclude that fibrates are ineffective in reducing residual cardio-
vascular risk. Composite evidence suggests cardiovascular efficacy
of pioglitazone, a thiazolidinedione (Lincoff et al, 2007). Yet, a
dual PPAR-a/c activator has failed to demonstrate clinical efficacy
(Lincoff et al, 2014). Selective PPAR-d (Choi et al, 2012) and dual
PPAR-a/d activators (Cariou et al, 2013) have been evaluated in
early phase clinical trials, but their cardiovascular efficacy remains
untested.
Phospholipase inhibitors
The phospholipase A2 family of enzymes hydrolyzes the sn-2 ester
bond of phospholipids in cell membranes and circulating lipopro-
teins, generating metabolites that may influence vascular function
and inflammation. Secretory phospholipase A2 (sPLA2) activity
results in the generation of smaller, more atherogenic LDL particles
and the generation of pro-inflammatory and oxidative metabolites
within the artery wall (Hurt-Camejo et al, 2001). However, a Phase
3 study evaluating the sPLA2 inhibitor varespladib in patients with
acute coronary syndrome demonstrated increased risk of recurrent
myocardial infarction (Nicholls et al, 2014). Lipoprotein-associated
phospholipase A2 (Lp-PLA2) is largely associated with LDL.
Elevated plasma concentrations or activity is associated with greater
cardiovascular risk. In early phase studies, the Lp-PLA2 inhibitor,
darapladib, demonstrated favorable effects on lipid and inflamma-
tory biomarkers and a reduction of the volume of necrotic core
within atherosclerotic plaques (Serruys et al, 2008). However, a
large outcome trial failed to demonstrate a benefit of darapladib on
cardiovascular death, myocardial infarction, or stroke (STABILITY
Investigators, 2014).
Conclusion
LDL-C, triglyceride-rich lipoproteins, and HDL-C may each play a
role in the development and progression of atherosclerosis and its
complications. For more than a quarter century, statins have been
the central element of lipid-modifying therapy to reduce cardiovas-
cular risk. However, residual cardiovascular risk on statin treatment
remains high. To date, no agent added to statins has yet been
proven to provide incremental clinical benefit. However, novel
approaches to further reduce LDL, to target triglyceride-rich lipopro-
teins, and to increase the concentration or functionality of HDL are
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under evaluation in basic investigations and in clinical trials, hold-
ing promise that tools to further reduce cardiovascular morbidity
and mortality may be forthcoming.
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